Study guide
12.3 Exceptions and Conditions Prohibiting Dispensing
Connecticut Multistate Pharmacy Jurisprudence Examination CT MPJE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the Connecticut MPJE 1.2 Application, Fees, ATT, and Pearson VUE 1.3 Blueprint, Scoring, Retakes, and Study Strategy
2 Connecticut Regulatory Structure
2.1 DCP and the Commission of Pharmacy 2.2 Chapter 400j, 420b/420c, and RCSA 20-576 2.3 Federal vs Connecticut Law (More Restrictive Rule)
3 Pharmacist Licensure, Interns, PIC, and CE
3.1 Pharmacist Qualifications and Exam Path 3.2 Interns, Score Transfer, and Reciprocity 3.3 Pharmacist-in-Charge / Pharmacist Manager 3.4 License Renewal and Continuing Education
4 Technicians and Non-Pharmacist Personnel
4.1 Technician Registration and Certification 4.2 Community Technician Ratios (20-576-36) 4.3 Institutional Ratios and Advanced Pharmacy Technicians 4.4 Technician Limitations, Interns, and Unlicensed Staff
5 Discipline, Impairment, and Unlicensed Practice
5.1 Disciplinary Grounds (CGS § 20-579) 5.2 Impaired Practitioner Reporting and Programs 5.3 Unlicensed Practice, Penalties, and Appeals
6 Federal Drug Law Foundations
6.1 FDCA, Adulteration, and Misbranding 6.2 FDA Approval, Recalls, and OTC vs Rx 6.3 DSCSA, HIPAA, OBRA ’90, and PPPA
7 Federal Controlled Substances
7.1 CSA Schedules and Definitions 7.2 DEA Registration and Forms 222, 106, 41 7.3 Federal Controlled-Substance Prescription Rules 7.4 Inventory, Theft, Loss, and Disposal
8 Prescription Issuance in Connecticut
8.1 Who May Prescribe in Connecticut 8.2 Noncontrolled Prescription Form and Content 8.3 Controlled Prescriptions and the EPCS Mandate
9 Refills, Partial Fills, and Opioid Limits
9.1 Refill Authority (Noncontrolled and CIII–V) 9.2 Partial Fills of Schedule II Prescriptions 9.3 Connecticut Opioid Supply Limits (7-day / 5-day)
10 Administration, CDTM, and Standing Orders
10.1 Pharmacist Immunization Authority 10.2 Collaborative Drug Therapy Management 10.3 Naloxone and Opioid Antagonist Access 10.4 Emergency and Hormonal Contraception
11 Counseling, Confidentiality, and Returns
11.1 Counseling and Offer to Counsel 11.2 HIPAA and Connecticut Confidentiality 11.3 Return, Reuse, and Take-Back
12 Corresponding Responsibility and DUR
12.1 Corresponding Responsibility and Legitimate Medical Purpose 12.2 Prospective Drug Utilization Review 12.3 Exceptions and Conditions Prohibiting Dispensing
13 Transfers, Labeling, Packaging, and Delivery
13.1 Transferring Prescriptions 13.2 Labeling of Dispensed Drugs 13.3 Packaging and the Poison Prevention Packaging Act 13.4 Delivery of Drugs
14 CPMRS, Substitution, and Nonprescription Drugs
14.1 CPMRS Query and Reporting 14.2 Generic and Biosimilar Substitution 14.3 CMEA and Behind-the-Counter Products 14.4 OTC Labeling, Hazardous, and Restricted Nonprescription Drugs
15 Ordering, Records, and Inventories
15.1 Ordering and Acquisition (DEA 222/CSOS) 15.2 Distribution and DSCSA Records 15.3 Recordkeeping Content and Three-Year Retention 15.4 Controlled-Substance Inventories and CT Perpetual CII
16 Storage, Security, and Hazardous Drugs
16.1 Controlled-Substance Storage and Security 16.2 Hazardous Drugs (USP <800>, NIOSH) 16.3 Non-Pharmacist Access to Drugs
17 Compounding and Central Fill
17.1 Nonsterile Compounding (USP <795>, RCSA 20-576-69) 17.2 Sterile Compounding (USP <797>, RCSA 20-576-64) 17.3 Central Fill, 503A, and 503B Outsourcing
18 Pharmacy Permits and Practice Settings
18.1 Pharmacy License, Hours, Manager, and Signage 18.2 Nonresident, Hospital, Nuclear, and Automated Dispensing 18.3 Inspection, Closure, and Facility Discipline
12.3 Exceptions and Conditions Prohibiting Dispensing
Key Takeaways Explain This Topic AI
Do not dispense a forged or altered prescription, a Schedule II refill, an out-of-scope order (veterinarian-for-human, dentist-for-unrelated chronic opioid, self/family CII–IV outside the 72-hour emergency in CGS § 21a-252), adulterated stock, or a Class I recalled lot still in active inventory.
CGS § 21a-249(h) bars filling or refilling a Schedule III or IV prescription more than six months after issuance. Connecticut has not published a numeric fill-by clock for Schedule II; corresponding responsibility still rejects a stale CII that is no longer in the usual course of care. Expired product in the active bay is adulterated under 21 U.S.C. § 351.
CGS § 20-612a requires valid photographic identification before releasing a controlled substance to a person not known to the pharmacist; the section does not apply in an institutional setting or to a long-term care facility, including assisted living.
An adult first-time outpatient opioid that clearly exceeds CGS § 20-14o’s 7-day default (5 days for a minor) without a documented subsection (d) exception is a refusal problem, not a courtesy fill. An emergency oral CII whose covering prescription is not mailed or delivered within 72 hours (CGS § 21a-249) cannot support further dispensing and requires DEA notification if the covering order never arrives.
Lawful exceptions: CGS § 20-616(c) allows one unauthorized noncontrolled refill of not more than a 72-hour supply when the prescriber cannot be reached and therapy would be interrupted; CGS § 20-616(d) lets—and, if the patient pays or has coverage, requires—a pharmacist to prescribe and dispense up to a 30-day insulin, glucagon, or ketoacidosis-device supply with 72-hour notice to the most recent prescriber.
Last updated: August 2026
When the correct answer is “do not fill”
Quick Answer: Do not dispense a forged or altered prescription, a Schedule II refill , an out-of-scope order, adulterated stock, a Class I recalled lot in active inventory, a controlled substance to a person not known without photographic ID ( CGS § 20-612a ), a first-fill opioid that clearly violates CGS § 20-14o without a documented exception, or an emergency oral CII whose covering prescription was not mailed or delivered within 72 hours ( CGS § 21a-249 ). Two statutes allow limited dispensing without a new prescriber order: § 20-616(c) (one 72-hour noncontrolled emergency refill) and § 20-616(d) (pharmacist-prescribed 30-day insulin, glucagon, or ketoacidosis devices, with 72-hour notice to the last prescriber).
NABP Competencies 3.4 (exceptions) and 3.7 (conditions prohibiting dispensing) are the same afternoon at a Connecticut bench. Section 12.1 is the judgment call when the blank looks real but the purpose does not. This section is the hard stops and the narrow doors that Chapter 400j actually wrote. Do not confuse the 72-hour emergency noncontrolled refill with the 72-hour covering-prescription clock for oral CII or the 72-hour notice after a pharmacist-prescribed insulin supply. Three different 72-hour sentences, three different jobs.
Hard stops — conditions that prohibit dispensing
Condition Why it is unfillable Principal authority
Forged or altered prescription It is not a prescription; filling it is illegal dispensing 21 CFR 1306.04(a) ; CGS § 20-579(a)(5)
Expired CIII–IV prescription Shall not be filled or refilled more than six months after the date issued CGS § 21a-249(h) ; 21 CFR 1306.22
Stale CII / expired CS product Connecticut has not published a numeric CII fill-by date; corresponding responsibility still rejects a CII that is no longer in the usual course of care. Expired tablets in the active bay are adulterated 21 CFR 1306.04 ; 21 U.S.C. § 351
CII refill Refilling Schedule II is prohibited 21 CFR 1306.12(a) ; CGS § 21a-249
Out-of-scope prescriber Veterinarian-for-human, dentist-for-unrelated back pain, optometrist-for-pneumonia, self/family CII–IV outside the 72-hour emergency CGS §§ 20-14c, 20-571, 21a-252(j)–(k) ; Chapter 8
Office-stock “prescription” A practitioner may not use a patient prescription to obtain CS for general dispensing 21 CFR 1306.04(b)
Class I recall in active stock Reasonable probability of serious harm or death; quarantine and stop dispensing those lots 21 CFR Part 7 ; Chapter 6.2
Adulterated or misbranded article FDCA forbids holding or dispensing it 21 U.S.C. §§ 351, 352
CS released without required ID Valid photographic identification before releasing a CS to a person not known to the pharmacist CGS § 20-612a
Opioid first-fill that clearly violates § 20-14o Adult first outpatient opioid default 7 days ; minor 5 days , unless (d) documents acute need, chronic pain, cancer pain, or palliative care CGS § 20-14o ; corresponding responsibility
Missing covering Rx after emergency oral CII Connecticut requires mailing or delivery of the covering prescription within 72 hours ; if it never arrives, notify DEA and do not treat the oral note as an ongoing CII CGS § 21a-249 ; 21 CFR 1306.11(d)
Forgery and alteration. A photocopied, traced, or quantity-changed CII is not a prescription. Authenticate with the prescriber. If the prescriber did not write it, do not fill , do not “change it back to 30 and fill,” and do not hand it back so the patient can try the next store without documenting the event. That is § 20-579(a)(5) territory if you release it.
Expired controlled-substance prescriptions versus expired product. CGS § 21a-249(h) is specific to Schedule III and IV : not filled or refilled more than six months after the date thereof, and not refilled more than five times , unless renewed. Schedule V is a medical-purpose drug under § 21a-249(i) (Chapter 9). Schedule II has no published Connecticut fill-by day count in § 21a-249 and no federal numeric expiration in 21 CFR 1306 . Do not import another state’s “30-day CII” rule. Do not fill a six-month-old oxycodone for acute dental pain as if nothing had changed— 1306.04 still asks whether it remains in the usual course of care. Expired product is a different prohibition: once the labeled expiration has passed, holding it in the active bay is adulteration ( 21 U.S.C. § 351 , Chapter 6.1).
Identity. CGS § 20-612a requires a pharmacist or the pharmacist’s agent to require valid photographic identification before releasing a controlled substance to any person not known to that pharmacist. The section does not apply in an institutional setting or to a long-term care facility, including, but not limited to, an assisted living setting. A known long-time patient of the pharmacist is not the statutory trigger. A stranger picking up oxycodone is. No ID when ID is required means do not release .
Class I recall. Class I means a reasonable probability of serious adverse health consequences or death (Chapter 6.2). Matching lots in robots, will-call, and the fast-mover bay are quarantined . Dispensing a Class I lot that is still in active stock is a quality failure and an adulteration/misbranding problem. Class II and III follow the firm’s notice; they are not a license to ignore Class I.
Opioid first-fill. CGS § 20-14o(b) limits an adult’s first-time outpatient opioid to a 7-day supply . § 20-14o(c) limits an opioid issued to a minor to a 5-day supply . Subsection (d) lets the practitioner exceed those numbers for a documented acute condition, chronic pain , cancer-associated pain , or palliative care , with a note that an alternative was not appropriate . A 30-day oxycodone for uncomplicated dental extraction, no (d) documentation, first outpatient fill, is not a “maybe.” Corresponding responsibility says do not fill as written . Calling the dentist for a 7-day quantity, or refusing, is the legal path. A documented palliative 30-day opioid is the exception the statute wrote—do not invent a “Connecticut never allows more than 7 days” rule (Chapter 9.3).
Emergency oral CII covering prescription. Federally the covering prescription may be postmarked within 7 days ( 21 CFR 1306.11(d) ). CGS § 21a-249 requires mailing or delivery within 72 hours . 72 hours wins in Connecticut. If the covering prescription never arrives , the pharmacist notifies the nearest DEA office ; failure to notify voids the authority to have dispensed. You do not keep filling from the oral note on day four.
Narrow doors — exceptions that allow dispensing
Chapter 400j writes two doors that are not corresponding-responsibility loopholes for oxycodone.
CGS § 20-616(c) — emergency refill of a noncontrolled prescription. All of the following must be true:
- The prescription is not for a controlled drug
- After reasonable effort , the pharmacist cannot contact the practitioner
- Failure to refill might interrupt a therapeutic regimen or create patient suffering
The pharmacist tells the patient at dispensing that the fill is unauthorized , and tells the practitioner at the earliest reasonable time that authorization is required for future refills
Then the prescription may be refilled once , for not more than a 72-hour supply . It is not a 30-day courtesy, not available for clonazepam, and not a remaining-refill generator.
CGS § 20-616(d) — pharmacist-prescribed diabetes supply. This is a new pharmacist prescription , not a refill of the old one, and it is not hidden in § 20-633 (immunization). DCP’s November 3, 2025 page and § 20-616(d) allow a pharmacist to immediately prescribe and dispense not more than a 30-day supply of a diabetic ketoacidosis device , insulin drug , or glucagon drug , plus devices needed to administer that supply, when:
The patient reports less than a 7-day supply
The pharmacist determines the patient will likely suffer significant physical harm within seven days without an additional supply
The pharmacist reviews CPMRS and determines no pharmacist has prescribed and dispensed such a supply to that patient within the last year (and contacts the pharmacy that filled the most recent prescription as needed to confirm)
Not later than 72 hours after dispensing, the pharmacist or representative notifies the practitioner who most recently prescribed the product
§ 20-616(d)(1)(B) then uses shall : if those criteria are met and the patient pays or has health insurance coverage for the product, the pharmacist shall prescribe and dispense. The 72 hours here is notice to the prescriber , not a 72-hour supply. Do not mix it with § 20-616(c) .
- Noncontrolled, office closed, 72-hour bottle → § 20-616(c)
- Insulin almost gone, 30-day pharmacist Rx, 72-hour call to the last prescriber → § 20-616(d)
- Oxycodone → neither door
- Scenario: Saturday hard stops and one lawful exception
A Bridgeport Saturday shift sees five requests. (1) A cash stranger wants oxycodone and has no photo ID — § 20-612a , do not release. (2) A first-fill adult dental oxycodone for 30 days with no § 20-14o(d) note — refuse as written and call. (3) A CII “refill” sticker on last month’s oxycodone — never. (4) A Class I lot of an injectable still in the robot — quarantine, do not dispense. (5) A lisinopril patient with no remaining refills, office closed, missed doses would interrupt therapy — one 72-hour noncontrolled supply under § 20-616(c) . An insulin patient with two days of analog left, significant harm likely this week, CPMRS showing no pharmacist-issued diabetes supply in the past year, and insurance that will pay, is the § 20-616(d) shall-dispense 30-day path, with notice to the last prescriber within 72 hours. Mixing those five into “we always help on weekends” is how the MPJE separates a pharmacist from a clerk.
CT may be stricter; more-restrictive wins.
Official anchors
21 CFR 1306.04 and 1306.11 — illegitimate orders; emergency oral CII covering prescription.
CGS § 21a-249 — CII no refills; 72-hour covering prescription; CIII–IV six-month / five-refill cap.
CGS § 20-14o — 7-day / 5-day opioid defaults and subsection (d) exceptions.
CGS §§ 20-612a, 20-616 — CS photo ID; 72-hour noncontrolled emergency refill; 30-day pharmacist-prescribed insulin/glucagon/DKA devices.
DCP diabetic drugs and devices — current 30-day criteria and 72-hour prescriber notice (updated November 3, 2025).